AU2009230776B2 - Neisseria meningitidis antigens and compositions - Google Patents
Neisseria meningitidis antigens and compositions Download PDFInfo
- Publication number
- AU2009230776B2 AU2009230776B2 AU2009230776A AU2009230776A AU2009230776B2 AU 2009230776 B2 AU2009230776 B2 AU 2009230776B2 AU 2009230776 A AU2009230776 A AU 2009230776A AU 2009230776 A AU2009230776 A AU 2009230776A AU 2009230776 B2 AU2009230776 B2 AU 2009230776B2
- Authority
- AU
- Australia
- Prior art keywords
- protein
- isolated
- nucleic acid
- acid molecule
- isolated protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims 8
- 241000588650 Neisseria meningitidis Species 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 229960005486 vaccine Drugs 0.000 claims abstract 2
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 241001212279 Neisseriales Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
Description
EDITORIAL NOTE APPLICATION NUMBER - 2009230776 The specification totals more than 1000 pages. Please contact IP Australia if you with to obtain a copy. Please note that the specification incorporates amendments filed on 10 February 2012.
Claims (26)
1. An isolated protein comprising: (i) an amino acid sequence selected from the group consisting of SEQ IDs 2876, 2878, 2880, 2882, 2884 and 2886; (ii) an amino acid sequence having x% or greater sequence identity to an amino acid sequence selected from the group consisting of SEQ IDs 2876, 2878, 2880, 2882, 2884 and 2886, where x is 50; or (iii) a fragment of at least n consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ IDs 2876, 2878, 2880, 2882, 2884 and 2886, wherein n is 10.
2. The isolated protein of claim 1, wherein x is 60.
3. The isolated protein of claim 1, wherein x is 70.
4. The isolated protein of claim 1, wherein x is 80.
5. The isolated protein of claim 1, wherein x is 90.
6. The isolated protein of claim 1, wherein x is 95.
7. The isolated protein of claim 1, wherein x is 99.
8. The isolated protein of claim 1, wherein n is 12.
9. The isolated protein of claim 1, wherein n is 14.
10. The isolated protein of claim 1, wherein n is 16.
11. The isolated protein of claim 1, wherein n is 18.
12. The isolated protein of claim 1, wherein n is 20.
13. An isolated antibody which binds to a protein according to any preceding claim.
14. An isolated nucleic acid molecule which encodes a protein according to any one of claims 1 to 12. 1421
15. The isolated nucleic acid molecule according to claim 14, comprising a nucleotide sequence selected from the group consisting of SEQ IDs 2875, 2877, 2879, 2881, 2883 and 2885.
16. An isolated nucleic acid molecule comprising a fragment of a nucleotide sequence selected from the group consisting of SEQ IDs 2875, 2877, 2879, 2881, 2883 and 2885, wherein said fragment comprises 23 or more consecutive nucleotides from said sequence.
17. An isolated nucleic acid molecule comprising a nucleotide sequence complementary to a nucleic acid molecule according to claim 15 or claim 16.
18. A composition comprising a protein, a nucleic acid molecule, or an antibody according to any preceding claim.
19. A composition according to claim 18 being a vaccine composition or a diagnostic composition.
20. A composition according to claim 18, being an immunogenic composition comprising a protein of any one of claims I to 12.
21. A vector comprising the nucleic acid molecule of any one of claims 14 to 17.
22. The vector of claim 21, which is an expression vector.
23. A host cell transformed with the vector of claim 21 or claim 22.
24. A process for producing a protein of any one of claims I to 12, comprising the step of culturing a host cell according to claim 23 under conditions which induce protein expression.
25. The use of a protein according to any one of claims I to 12 in the manufacture of a medicament for the treatment or prevention of infection due to Neisserial bacteria.
26. A method for the treatment or prevention of infection due to Neisserial bacteria comprising administering to a subject in need of such treatment an effective amount of the protein according to any one of claims I to 12, an antibody according to claim 1422 13, a nucleic acid according to any one of claims 14 to 17, and/or a composition according to any one of claims 18 to 20.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009230776A AU2009230776B2 (en) | 1998-05-01 | 2009-10-26 | Neisseria meningitidis antigens and compositions |
| AU2012203235A AU2012203235B2 (en) | 1998-05-01 | 2012-05-31 | Neisseria meningitidis antigens and compositions |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/083758 | 1998-05-01 | ||
| US60/094869 | 1998-07-31 | ||
| US60/099062 | 1998-09-02 | ||
| US60/098994 | 1998-09-02 | ||
| US60/103794 | 1998-10-09 | ||
| US60/103796 | 1998-10-09 | ||
| US60/103749 | 1998-10-09 | ||
| US60/121528 | 1999-02-25 | ||
| AU2003235364A AU2003235364C1 (en) | 1998-05-01 | 2003-07-21 | Neisseria meningitidis antigens and compositions |
| AU2006202355A AU2006202355B2 (en) | 1998-05-01 | 2006-06-02 | Neisseria meningitidis antigens and compositions |
| AU2009230776A AU2009230776B2 (en) | 1998-05-01 | 2009-10-26 | Neisseria meningitidis antigens and compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006202355A Division AU2006202355B2 (en) | 1998-05-01 | 2006-06-02 | Neisseria meningitidis antigens and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012203235A Division AU2012203235B2 (en) | 1998-05-01 | 2012-05-31 | Neisseria meningitidis antigens and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009230776A1 AU2009230776A1 (en) | 2009-11-26 |
| AU2009230776B2 true AU2009230776B2 (en) | 2012-03-01 |
Family
ID=36616713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006202355A Ceased AU2006202355B2 (en) | 1998-05-01 | 2006-06-02 | Neisseria meningitidis antigens and compositions |
| AU2009230776A Ceased AU2009230776B2 (en) | 1998-05-01 | 2009-10-26 | Neisseria meningitidis antigens and compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006202355A Ceased AU2006202355B2 (en) | 1998-05-01 | 2006-06-02 | Neisseria meningitidis antigens and compositions |
Country Status (1)
| Country | Link |
|---|---|
| AU (2) | AU2006202355B2 (en) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3940598A1 (en) * | 1989-12-08 | 1991-06-13 | Behringwerke Ag | TOXOPLASMA GONDII-ANTIGENE, THEIR PRODUCTION AND USE |
| US5587306A (en) * | 1995-04-10 | 1996-12-24 | Incyte Pharmaceuticals, Inc. | Phospholipase C homolog |
| US6172192B1 (en) * | 1996-01-26 | 2001-01-09 | Innogenetics N.V. | Toxoplasma gondii antigen Tg20 |
| US6307020B1 (en) * | 1996-01-31 | 2001-10-23 | Hsc Research And Development Ltd. Partnership | Intracellular antifreeze polypeptides and nucleic acids |
| JP3335287B2 (en) * | 1996-03-15 | 2002-10-15 | 旭化成株式会社 | Hexokinase gene |
| US7393663B2 (en) * | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| US6222029B1 (en) * | 1997-08-01 | 2001-04-24 | Genset | 5′ ESTs for secreted proteins expressed in brain |
| US6380370B1 (en) * | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US20010051335A1 (en) * | 1998-04-21 | 2001-12-13 | Raghunath V. Lalgudi | Polynucleotides and polypeptides derived from corn tassel |
-
2006
- 2006-06-02 AU AU2006202355A patent/AU2006202355B2/en not_active Ceased
-
2009
- 2009-10-26 AU AU2009230776A patent/AU2009230776B2/en not_active Ceased
Non-Patent Citations (8)
| Title |
|---|
| Bell-Pedersen et al (1996) PNAS, 93:13096 * |
| Bonaldo et al (1996) Genome Res, 6(9):791-806 * |
| GenBank Accession Number AA898626 * |
| GenBank Accession Number AW723221, AW715022, AW715023 * |
| GenBank Accession Number C73535 * |
| GenBank Accession Number CF947567 * |
| GenBank Accession Number MUSIL4R01 * |
| Wrighton et al (1992) Growth Factors, 6(2):103-118 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006202355A1 (en) | 2006-06-22 |
| AU2006202355B2 (en) | 2009-08-20 |
| AU2009230776A1 (en) | 2009-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2438080A1 (en) | Gonococcal proteins and nucleic acids | |
| RU2339646C2 (en) | Hybrid and tandem expression of neisseria proteins | |
| JP3595264B2 (en) | Low toxicity LPS from genetically modified Gram-negative bacteria | |
| Restrepo et al. | Antigen diversity in the bacterium B. hermsii through “somatic” mutations in rearranged vmp genes | |
| RU2007139915A (en) | HAEMOPHILUS INFLUENZAE TYPE B | |
| BR9914374A (en) | Genetic sequences of neisseria and methods for its use | |
| NL300896I2 (en) | Neisseira meningitidis serogroup B recombinantly lipidated fHbp subfamily B01 protein | |
| JP2010512792A5 (en) | ||
| RU2002117308A (en) | 85 kDA ANTIGEN NEISSERIA | |
| US5571718A (en) | Cloning and expression of soluble truncated variants of Borrelia OspA, OspB and Vmp7 | |
| CN1671845A (en) | Immunogen sequence | |
| Thomas et al. | Characterization of flagellum gene families of methanogenic archaea and localization of novel flagellum accessory proteins | |
| JPS61143327A (en) | Multi-effective immunologic protein | |
| CA2461443A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
| CA2217522A1 (en) | Isolated frpb nucleic acid molecule and vaccine | |
| US6444799B1 (en) | P. gingivalis polynucleotides and uses thereof | |
| CA2195090A1 (en) | Lkp pilin structural genes and operon of nontypable haemophilus influenzae | |
| DE69227898T2 (en) | RECOMBINANT HYBRID PORINE PITOPE | |
| AU2009230776B2 (en) | Neisseria meningitidis antigens and compositions | |
| CN110804102B (en) | Group B meningococcal vaccine, and preparation method and application thereof | |
| TW200806689A (en) | Polynucleotides of haemophilus parasuis and its use | |
| US7618635B2 (en) | Super-antigen fusion proteins and the use thereof | |
| JP2011116659A (en) | Medicine for swine atrophic rhinitis comprising recombinant dermonecrotic toxoid | |
| CA2223503A1 (en) | Transferrin receptor genes | |
| RU2223492C2 (en) | Protein obtained from neisseria meningitidis (variants, its fragment, nucleic acid encoding thereof (variants), probe, primer, composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; J. CRAIG Free format text: FORMER APPLICANT(S): NOVARTIS VACCINES AND DIAGNOSTICS, INC.; THE INSTITUTE FOR GENOMIC RESEARCH |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FRASER, CLAIRE; GALEOTTI, CESIRA; GRANDI, GUIDO; HICKEY, ERIN; MASIGNANI, VEGA; MORA, MARIAROSA; PETERSEN, JEREMY; PIZZA, MARIAGRAZIA; RAPPUOLI, RINO; RATTI, GIULIO; SCALATO, ENZO; SCARSELLI, MARIA; TETTELIN, HERVE AND VENTER, J. CRAIG . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FRASER, CLAIRE; GALEOTTI, CESIRA; GRANDI, GUIDO; HICKEY, ERIN; MASIGNANI, VEGA; MORA, MARIAROSA; PETERSEN, JEREMY; PIZZA, MARIAGRAZIA; RAPPUOLI, RINO; RATTI, GIULIO; SCALATO, ENZO; SCARSELLI, MARIA; TETTELIN, HERVE AND VENTER, J. CRAIG |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA Free format text: FORMER OWNER(S): NOVARTIS VACCINES AND DIAGNOSTICS, INC.; J. CRAIG VENTER INSTITUTE, INC. |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |